Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > anything below restructure point of 15$ is an excellent

<< Previous

Bullboard Posts

Next >>

Comment by GunnerGon May 21, 2020 1:01pm

55 Views

Post# 31056894

RE:anything below restructure point of 15$ is an excellent

You are confusing Fast Track and Priority Review. They are different animals.

Newcamo wrote:
entry point! Fast track for BLA/riplazym is a given imo, it was fast tracked the first time, we are submitting the same product (LMNL says it should be fast tracked as the first time). We only added checkpoints in the plant, all done and tested 100% success. FDA shoould give its ok in LESS than 6 months, so end of year ( it was flawless the first review, FDA wanted extra check points that are done now ). Partnership for distribution $$$ should come next weeks.

"2020 remains an important and eventful year for the Company. While there are uncertainties for the year ahead, we remain focused on the resubmission of our Biologic License Application, or BLA to the Food and Drug Administration, or FDA for Ryplazim® (plasminogen), or Ryplazim® as a treatment of patients with congenital plasminogen deficiency, and the development of our small molecule pipeline . We also continue to plan and explore alternatives for the commercial launch of Ryplazim®, initially in the United States, if approved. We will continue to monitor and provide more updates as the situation unfolds."